regulatory-strategy
(22)
The Firm That Learned to Sell the Map of Washington
For fifty years, Cassidy & Associates has sold something more durable than access: a working model of how decisions move through Washington - and a team built to move with them.
The Lobbying Firm That Put the Whole Campaign Under One Roof
CGCN sells access, analysis, storytelling, and outside pressure as one coordinated system. A 20-year campaign for salon tax relief shows why the parts matter most when they move together.
The Lobbying Firm That Had to Learn Washington Twice
Van Scoyoc Associates built a formidable business around one path through Congress. When that path closed, the firm discovered that influence is less a doorway than a map.
The Company That Sells the Last Mile of Permission
A market can be open on paper and closed in practice. Asia Group Advisors built a business in that gap - finding the official, argument, permit or coalition that turns permission into progress.
The Campaign Never Ended. It Just Moved Into the Boardroom.
BHA Strategy borrowed the machinery of a political campaign - intelligence, narrative, coalition and cadence - and rebuilt it for organizations whose growth depends on what government does next.
The Thirty-Person Firm That Learned to Read Albany's Weather
Ostroff Associates built a top-five New York lobbying practice by treating politics less like theater and more like weather: watch every front, know the terrain, and tell clients when to move.
The Lobbyists Who Lost the Bill - and Won the Exemption
Public Strategies Washington sells access, judgment and a useful refusal to confuse the first plan with the real objective. Its best case study begins with a defeat in Congress - then moves across town and ends with an exemption worth hundreds of thousands of dollars per client.
The $900,000 Sentence Hidden Inside Medicare
Applied Policy works in the quiet gap between medical possibility and federal payment. Its specialty is finding the sentence, code, status indicator, or application that can turn a promising treatment into care someone can actually receive.
The Campaign Never Ends - It Just Changes Clients
Jim Messina took the machinery of a presidential race and rebuilt it for companies, causes and crises. The revealing part is not the famous wins - it is what the firm does when the original plan stops working.
The Lobbyists Who Put Customers in the Room
Tusk Strategies found a lucrative gap between lobbying and campaigning: when policy threatens a business, it recruits the people who will miss it most.
Ervin Graves Knows the Price of a Good Line Item
In Washington, policy becomes real when somebody can navigate the people, the calendar and the money. Ervin Graves Strategy Group sells that navigation - one tailored campaign at a time.
The Door Was Never the Product
Miller Strategies built a Washington business around access. Its more interesting trick was proving that access only becomes durable when it is packaged as information, timing and relentless follow-through.
Axiom Advisors and the business of getting California to say yes
Axiom Advisors is putting lobbyists, campaigners and communicators under one roof. Its wager: a company’s toughest California problem rarely stays inside the Capitol.
FinTech Consult Sells the Six Months You Cannot Afford to Waste
A 19-person network in 18 markets helps fintech founders turn a country on a slide into customers, partners and regulatory conversations on the ground. The proposition is refreshingly plain: buy local context before you buy an overseas mistake.
Five Engineers, Twenty-Five Pounds and a Workshop for Medicine
Team Consulting nearly disappeared before it found its lane. Four decades later, its employee-owners build the unglamorous machinery behind better injections, longer-lived transplant organs and an ear clinic that fits in a hand.
Eiry Roberts Built the Bridge From Lab Bench to Boardroom
Across 26 years at Lilly and seven as Neurocrine's chief medical officer, Eiry Roberts learned that drug development is less a straight line than a chain of judgment calls. Her next chapter puts that operating memory to work in the boardroom.
The Birmingham startup that made pharma pay for trust it never earned
Del Smith and Tiffany Whitlow built a 200,000-member community first and an AI second - and got seven of the ten biggest drug makers to buy the trust they earned.
Overture Ventures
Most climate investors bring capital and a network. Overture adds a policy desk - helping technical founders turn the machinery of government from a maze into a market advantage.
Karen Chu
Karen Chu is the founder and CEO of HiRO (Harvest Integrated Research Organization), a boutique global contract research organization that bridges clinical trials between Asia, the US, and Europe. A PharmD who spent nearly two decades at Parexel running global clinical operations across 50-plus countries, she launched HiRO in 2020 to help Asian biotechs run trials abroad and Western firms run trials in Asia. Under her leadership the company has expanded through acquisitions including Courante Oncology in the US and PharmaSols in Australia and New Zealand, while positioning itself as global in reach but deliberately mid-sized in ambition.
Louis Licamele
Louis Licamele, PhD is a computer scientist turned drug developer who serves as Chief Development Officer and EVP of Clinical and Data Science at Bloom Science, a San Diego biotech building microbiome-based, ketogenic-mimicking live biotherapeutics for obesity and neurological disease. A founding team member, he oversees biostatistics, clinical data management, and data-driven trial design for the company's lead candidate BL-001. He built his career at the intersection of data and medicine - a BS in biology and computer science from Georgetown, a PhD in computer science from the University of Maryland, and senior informatics and biometrics roles at Vanda Pharmaceuticals and REGENXBIO. He also runs The Licamele Group, advising healthcare companies on data science, AI, and regulatory strategy.
Nventric, Inc.
Nventric, Inc. is a medical device company and contract development and manufacturing organization (CDMO) headquartered in Arcadia, California, with operations in Seoul, South Korea. Founded in 2019 by engineers with backgrounds at Abbott Vascular and Johnson & Johnson, Nventric designs and builds minimally invasive vascular devices - covering neurovascular, coronary, and electrophysiology applications - from concept through scalable, ISO 13485-certified manufacturing. Its own-branded neurovascular line, including the ULTRIVA stent retriever and EVOGLIDE distal access catheter, targets acute ischemic stroke, while its OEM/CDMO services help device companies move products from prototype to commercialization.
Evan Neu
Evan Neu is Partner and General Counsel at Venrock, the storied venture capital firm born out of the Rockefeller family's investment legacy. Based in Palo Alto, he leads the firm's legal and regulatory strategy while overseeing operations and administration. Before joining Venrock in November 2022, Neu served as Managing Director and Deputy General Counsel at TPG, one of the world's leading global alternative asset managers, and earlier built his legal foundation as an Associate at Debevoise & Plimpton LLP in New York. He holds a B.S. from Cornell University and a J.D. from the University of Pennsylvania Law School.